Osteosarcoma
HC Beird, SS Bielack, AM Flanagan, J Gill… - Nature reviews Disease …, 2022 - nature.com
Osteosarcoma is the most common primary malignant tumour of the bone. Osteosarcoma
incidence is bimodal, peaking at 18 and 60 years of age, and is slightly more common in …
incidence is bimodal, peaking at 18 and 60 years of age, and is slightly more common in …
Recent and ongoing research into metastatic osteosarcoma treatments
MA Harris, CJ Hawkins - International Journal of Molecular Sciences, 2022 - mdpi.com
The survival rate for metastatic osteosarcoma has not improved for several decades, since
the introduction and refinement of chemotherapy as a treatment in addition to surgery. Over …
the introduction and refinement of chemotherapy as a treatment in addition to surgery. Over …
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
N Gaspar, R Venkatramani, S Hecker-Nolting… - The Lancet …, 2021 - thelancet.com
Background Tyrosine kinase inhibitors have shown activity in osteosarcoma and might
enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 …
enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 …
[HTML][HTML] Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label …
L Xie, J Xu, X Sun, W Guo, J Gu, K Liu… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Results of our previous study showed high objective response but short-term
activity of apatinib in advanced osteosarcoma. We aimed to investigate the activity of …
activity of apatinib in advanced osteosarcoma. We aimed to investigate the activity of …
Current research progress in targeted anti‐angiogenesis therapy for osteosarcoma
Y Liu, N Huang, S Liao, E Rothzerg, F Yao… - Cell …, 2021 - Wiley Online Library
Osteosarcoma (OS) is the most common primary malignant bone tumour with a peak in
incidence during adolescence. Delayed patient presentation and diagnosis is common with …
incidence during adolescence. Delayed patient presentation and diagnosis is common with …
Receptor tyrosine kinases in osteosarcoma treatment: which is the key target?
Z Tian, X Niu, W Yao - Frontiers in Oncology, 2020 - frontiersin.org
Recent clinical trials have shown several multi-target tyrosine kinase inhibitors (TKIs) to be
effective in the treatment of osteosarcoma. However, these TKIs have a number of targets …
effective in the treatment of osteosarcoma. However, these TKIs have a number of targets …
Osteosarcoma: current concepts and evolutions in management principles
P Pilavaki, A Gahanbani Ardakani, P Gikas… - Journal of Clinical …, 2023 - mdpi.com
Osteosarcoma is a rare malignancy arising from mesenchymal tissue, and represents the
most common bone sarcoma. The management of osteosarcoma is challenging, and …
most common bone sarcoma. The management of osteosarcoma is challenging, and …
In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy
L Yu, G Fan, Q Wang, Y Zhu, H Zhu, J Chang… - Cell Death & …, 2023 - nature.com
The prognosis of lung metastatic osteosarcoma (OS) remains disappointing. siRNA-based
gene silencing of VEGFR2 is a promising treatment strategy for lung metastatic OS, but there …
gene silencing of VEGFR2 is a promising treatment strategy for lung metastatic OS, but there …
[HTML][HTML] Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma …
N Gaspar, Q Campbell-Hewson, SG Melcon, F Locatelli… - ESMO open, 2021 - Elsevier
Background We report results from the phase I dose-finding and phase II expansion part of a
multicenter, open-label study of single-agent lenvatinib in pediatric and young adult patients …
multicenter, open-label study of single-agent lenvatinib in pediatric and young adult patients …
[HTML][HTML] A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?
R van Ewijk, M Cleirec, N Herold, MC le Deley… - Cancer Treatment …, 2023 - Elsevier
Abstract Background/Objective To analyze changes in recurrent/refractory osteosarcoma
phase II trials over time to inform future trials in this population with poor prognosis. Methods …
phase II trials over time to inform future trials in this population with poor prognosis. Methods …